These studies demonstrate that the anti-cancer effects of PFI-3 are contingent on whether the SWI/SNF VIII bromodomains are required for SWI/SNF recruitment to specific genomic sites that promote tumorigenesis or affect sensitivity to other chemotherapeutics. This evidence concerns the gene SMARCA1 and cancer.